mRNA based vaccines provide broad protection against different SARS-CoV-2 variants of concern
Year: 2022
Type: article
Abstract: In order to overcome the pandemic of COVID-19, messenger RNA (mRNA)-based vaccine has been extensively researched as a rapid and versatile strategy. Herein, we described the immunogenicity of mRNA-based vaccines for Beta and the most recent Omicron variants. The homologous mRNA-Beta and mRNA-Omicron and heterologous Ad5-nCoV plus mRNA vaccine exhibited high-level cross-reactive neutralization for Beta, original, Delta, and Omicron variants. It indicated that the COVID-19 mRNA vaccines have great potential in the clinical use against different SARS-CoV-2 variants.
Source: Emerging Microbes & Infections
Authors: Haomeng Wang, Zhao Chen, Zhenghua Wang, Jin Li, Zhihong Yan, Jinbo Yuan, Airu Zhu, Lan Chen, Ye Liu, Chenlong Hu, Ali Zhu, Guowei Li, Yuehu Li, Jie Deng, Liqiao Ma, Xiuwen Sui, Wei Miao, Junqiang Li, Xiuyu Zheng, Jinhua Piao, Yanfeng Yao, Juhong Rao, Chao Shan, Zhiming Yuan, Jincun Zhao, Tao Zhu
Institutions: CanSino (China), First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Health, Chinese Academy of Sciences, Wuhan Institute of Virology, State Key Laboratory of Virology, ShanghaiTech University, Guangzhou Eighth People's Hospital, Guangzhou Laboratory, Guangzhou Medical University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,643
Award: G3417858882
OpenAlex ID: W4281293683